Longitudinal follow up of a phase 2 trial of venetoclax added to hyper-CVAD, nelarabine and pegylated asparaginase in patients with T-cell acute lymphoblastic leukemia and lymphoma
Leukemia · 2024-12 · 38 (12) · 2717-2721
DOI: 10.1038/s41375-024-02414-4 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Leukemia, online erschienen am 25.09.2024. Verfasst von Farhad Ravandi und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Leukemia, The University of Texas MD Anderson Cancer center, Houston, TX, USA. fravandi@mdanderson.org. Hauptthemen laut MEDLINE: Asparaginase, Antineoplastic Combined Chemotherapy Protocols, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Bridged Bicyclo Compounds, Heterocyclic. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 15 Literaturangaben.
Abstract (Originalsprache)
Optimal frontline use of active agents in T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/LBL) is prudent to improve outcomes. We report the long-term follow-up of the phase 2 trial of HyperCVAD with nelarabine and pegylated asparaginase (Original cohort). In the latest protocol iteration venetoclax was added to the induction/consolidation regimen (Venetoclax cohort). Eligible patients were adults with untreated T-ALL/LBL or after minimal therapy and with adequate organ function. Primary endpoint of this analysis was improvement in 2-year progression free survival (PFS) and overall survival (OS) with venetoclax. From Aug 2007 to Dec 2024, 145 patients, at a median age of 35.4 years, were treated; 46 (33.8%) were in the venetoclax cohort. At median follow-up (mFU) of 62.4 months, 5-year PFS, duration of response (DOR), and OS were 63.7%, 72.0% and 66.2% respectively. In the venetoclax cohort (mFU 24.4 months) 2-year PFS (87.9% versus 64.1%, p = 0.03) and 2-year DOR (93.6% versus 69.2%, p = 0.005) were superior to the original cohort (mFU 89.4 months) and 2-year OS appeared better (87.8% versus 73.9%, p = 0.16). Febrile neutropenia was the most common serious adverse event, seen in 60% patients. The addition of venetoclax to HyperCVAD-nelarabine-pegylated asparaginase was tolerable and led to improvement in DOR and PFS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Leukemia, The University of Texas MD Anderson Cancer center, Houston, TX, USA. fravandi@mdanderson.org.
- Department of Leukemia, The University of Texas MD Anderson Cancer center, Houston, TX, USA.
- Department of Biostatistics, The University of Texas MD Anderson Cancer center, Houston, TX, USA.
- Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer center, Houston, TX, USA.
ORCID-Profile: Farhad Ravandi, Jayastu Senapati, Nicholas J Short, Tapan Kadia, Gautam Borthakur, Marina Konopleva, William Wierda, Xuelin Huang, Guillermo Garcia-Manero, Yesid Alvarado, Elias Jabbour, Hagop M Kantarjian
Zitieren
APA
Ravandi, F., Senapati, J., Jain, N., Short, N. J., Kadia, T., Borthakur, G., Konopleva, M., Wierda, W., Huang, X., Maiti, A., Issa, G., Balkin, H., Garris, R., Ferrajoli, A., Garcia-Manero, G., Alvarado, Y., Kebriaei, P., Jabbour, E., & Kantarjian, H. M. (2024). Longitudinal follow up of a phase 2 trial of venetoclax added to hyper-CVAD, nelarabine and pegylated asparaginase in patients with T-cell acute lymphoblastic leukemia and lymphoma. Leukemia, 38(12), 2717-2721. https://doi.org/10.1038/s41375-024-02414-4
Vancouver
Ravandi F, Senapati J, Jain N, Short NJ, Kadia T, Borthakur G, et al. Longitudinal follow up of a phase 2 trial of venetoclax added to hyper-CVAD, nelarabine and pegylated asparaginase in patients with T-cell acute lymphoblastic leukemia and lymphoma. Leukemia. 2024;38(12):2717-2721. doi:10.1038/s41375-024-02414-4
BibTeX
@article{Ravandi2024,
author = {Ravandi, Farhad and Senapati, Jayastu and Jain, Nitin and Short, Nicholas J and Kadia, Tapan and Borthakur, Gautam and Konopleva, Marina and Wierda, William and Huang, Xuelin and Maiti, Abhishek and Issa, Ghayas and Balkin, Hayley and Garris, Rebecca and Ferrajoli, Alessandra and Garcia-Manero, Guillermo and Alvarado, Yesid and Kebriaei, Partow and Jabbour, Elias and Kantarjian, Hagop M},
title = {Longitudinal follow up of a phase 2 trial of venetoclax added to hyper-CVAD, nelarabine and pegylated asparaginase in patients with T-cell acute lymphoblastic leukemia and lymphoma},
journal = {Leukemia},
year = {2024},
volume = {38},
number = {12},
pages = {2717--2721},
doi = {10.1038/s41375-024-02414-4}
}
EUVIMED